Laurus Labs Extends Gains As B&K Initiates Coverage, Projects 18% Upside

Laurus Labs shares edged higher during the special Diwali muhurat trading.

Laurus Labs shares edged higher during the special Diwali muhurat trading.(Source: Laurus Labs/X)

Laurus Labs Ltd. share price rose on Tuesday as B&K Securities initiated coverage and projected an 18% upside potential for the stock price. The pharma company is set to begin a strong growth cycle as its main earning-driving segment margin expands.

Contract development and manufacturing organisation — the key growth driving segment of Laurus Labs — delivered a Rs 1,370 crore revenue in financial year 2025, which marks a 49% year-on-year increase. Over 110 active programs, increasing late-stage conversion, and strategic diversification into animal health and crop sciences have supported this growth, B&K Securities said in a report.

Laurus Labs will likely sustain 40% compound annual growth rate in revenue from small molecule CDMO over FY25-FY28, according to B&K.

The company has directed the majority of the Rs 4,000-crore or $450-million capital expenditure towards CDMO capabilities over the last five years. These capabilties include biocatalysis, fermentation, and high-potent chemistry with further Rs 2,000 crore or $232 million earmarked for the next two years.

As the sales mix shift toward the high-value segment, Ebitda margins are projected to expand from 19% in FY25 to 28% in FY28, driving a 51% CAGR in net profit over the same period.

Track live updates on Muhurat Trading here.

Laurus Labs shares were 0.48% higher at Rs 925 apiece as of 1:58 p.m., compared to 0.19% advance in the NSE Nifty 50 index.

The stock advanced 98.83% in 12 months, and 53.48% on year-to-date basis. The relative strength index was at 65.90.

Out of 17 analysts tracking the company, eight maintain a 'buy' rating, three recommend a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies a downside of 11.6%.

Also Read: Muhurat Trading: Piramal Pharma, Blue Jet Healthcare In Focus — Check New Stock Rating, Price Target

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
WRITTEN BY
Ananya Chaudhuri
Ananya Chaudhuri covers financial markets news and trends at NDTV Profit. S... more
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google